Principal Financial Group
ALDX icon

Principal Financial Group’s Aldeyra Therapeutics ALDX Stock Holding History

Principal Financial Group’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,475
Closed -$92K – 2528
2021
Q3 		$92K Sell
10,475
-431
-4% -$3.96K ﹤0.01% 2508
2021
Q2 		$124K Buy
+10,906
New +$131K ﹤0.01% 2515

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Principal Financial Group's ALDX Position: Q4 2021 in Review

Principal Financial Group sold out of Aldeyra Therapeutics (ALDX) in Q4 2021, closing a stake of 10,475 shares — an estimated $92K sold.

Principal Financial Group first reported a position in ALDX in Q2 2021 and held it in 2 quarters. The position peaked at $124K in Q2 2021. 115 funds tracked by Wall St. Rank hold ALDX as of Q4 2021.

  • Principal Financial Group reported no remaining Aldeyra Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Principal Financial Group sold 10,475 Aldeyra Therapeutics shares in Q4 2021, an estimated $92K.
  • Principal Financial Group first reported a position in Aldeyra Therapeutics in Q2 2021 and held it in 2 quarters.
  • Principal Financial Group's Aldeyra Therapeutics position peaked at $124K in Q2 2021.
  • 115 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2021.

Based on Principal Financial Group's 13F filing for Q4 2021, filed 9 Feb 2022.